Trade Names:Sotradecol- Injection 10 mg/mL- Injection 30 mg/mL
Causes venous intima inflammation and thrombus formation, which occludes the injected vein and subsequently forms fibrous tissue that results in partial or complete vein obliteration.
Treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.
Bleeding esophageal varices.
Acute superficial thrombophlebitis; valvular or deep vein incompetence; huge superficial veins with wide open communications to deeper veins; phlebitis migrans; acute cellulitis; allergic conditions; acute infections; varicosities caused by abdominal and pelvic tumors unless tumor has been removed; bedridden patients; uncontrolled systemic diseases such as diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, acute respiratory or skin disease; hypersensitivity to any component of the product.
IV Dose varies with size and degree of varicosity. In general, 1% solution is most useful, and the 3% solution is preferred for larger varicosities.
Store vials at controlled room temperature (68° to 77°F).
None well documented.Incompatibilities
Heparin should not be included in the same syringe.
None well documented.
Permanent discoloration along path of sclerosed vein.
Pain; sloughing and necrosis of tissue following extravasation; ulceration at injection site; urticaria.
Allergic reactions including anaphylactic shock, asthma, hay fever, and hives.
Category C .
Safety and efficacy not established.
Use with extreme caution in the presence of underlying arterial disease (eg, marked peripheral arteriosclerosis, thromboangiitis obliterans).
The risk of thrombosis extension into the deep venous system exists.
Copyright © 2009 Wolters Kluwer Health.